lifespin GmbH
Booth number: C23
www.lifespin.health
About us
Digitizing human health offers health insights at your fingertips. lifespin is a smart diagnostics technology platform merging biology, deep data, artificial intelligence, and cloud technologies to enable digital metabolic insights for: precision diagnostics, personalized treatment of diseases, lifestyle interventions, and drug monitoring for pharmaceutical, research, and clinical settings.
We have standardized the baseline for human health and can detect distinct deviations caused by diseases. Diseases impact metabolism and the presence and quantity of metabolites.
Our proprietary technology platform digitally captures individual metabolomes, i.e., hundreds of metabolite concentrations with a single Nuclear Magnet Resonance (NMR) measurement.
Our constantly growing database of digital metabolic profiles, with currently more than 200k individuals, enables the analysis of more than one billion metabolic relationships.
Address
Am BioPark 13
93053 Regensburg
Germany
Phone: +49 941 94289817
One Boston Place Suite 2600
Boston 02108
U.S.A.
E-mail: ali.tinazli@lifespin.health
Internet: www.lifespin.health
Contact person:
Dr. Ali Tinazli
Chief Executive Officer
E-mail: ali.tinazli@lifespin.health
Phone: +49 160 2573458
Dr. Diana Drettwan
Head of Customer Management
E-mail: diana.drettwan@lifespin.health
Phone: +49 941 94289817
Products & Services
lifespin revolutionizes diagnostics with new product categories resulting from the convergence of data science and biology.
Digital metabolic profiles enable differential diagnosis of health conditions, staging of diseases, monitoring of treatment success, and personalized medicine. lifespin´s AI-enabled technology platform is a versatile, highly scalable, cloud-based value creation engine, to provide moderate cost diagnostics.
Currently, we offer products for medical research, pharmaceutical drug development and clinical trial support: e.g. Biomarker panels (e.g. amino acids or lipids) and drug monitoring in blood, urine etc.
Our first regulatory approved health testing software-as-a-service (SaaS) will be for the early diagnosis of prostate cancer and is expected in 2023. This will be followed by other tests for the detection of neurological, cancer, and inflammatory diseases.
Our cloud-based business model is built on our proprietary SaaS platform for diagnostics and health information and is globally scalable.
